Today: 19 July 2026
Browse Category

NASDAQ:CDTX 24 September 2025 - 9 January 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck & Co Inc shares were up about 0.4% at $111.41 on Friday as investors weighed a report that the drugmaker is in talks to buy cancer biotech Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped nearly 16% in extended trading on Thursday after the Financial Times report, which said talks were not final and could still take weeks, with other large drugmakers still circling; Merck and Revolution did not respond to requests for comment. The potential acquisition would be the biggest in the sector since Pfizer’s $43 billion Seagen deal and would add Revolution’s late-stage RAS cancer drug candidate daraxonrasib; Mizuho analysts estimate Revolution’s RAS inhibitors could generate more than $10 billion in risk-adjusted sales by 2035 as Merck looks past Keytruda patent expiries later this decade.
9 January 2026
···
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck & Co shares edged down in after-hours trading on Wednesday after U.S. health officials updated the childhood immunization schedule and moved to a single dose for the human papillomavirus vaccine, a change that could pressure demand for Merck’s Gardasil shot. The stock was down about 0.2% at $108.60, after trading between $107.99 and $111.42 in the regular session. HHS.gov
8 January 2026
····
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck & Co shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics and expected to finish the acquisition through a merger later in the day. The company said the deal will be treated as an asset acquisition, lifting 2026 research and development expense by about $9.0 billion and cutting earnings per share by roughly 30 cents in the first 12 months. “The acquisition of Cidara strengthens and complements our expanding respiratory portfolio,” Chief Executive Robert M. Davis said. Merck.com
7 January 2026
·····
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck & Co. shares ended Friday up about 1.2% at $106.45. Nasdaq said the cash tender offer for Cidara Therapeutics is scheduled to expire one minute after 11:59 p.m. ET on Jan. 6, with the merger tentatively slated to close before the market opens Jan. 7. The exchange said Cidara shares would be halted after the after-hours session on Jan. 6 and suspended Jan. 8 if the deal closes as planned. NASDAQ Trader
3 January 2026
···
5 Most Interesting Nasdaq Stocks Today (November 14, 2025): AMAT, CDTX, NVDA, AAPL & TSLA

5 Most Interesting Nasdaq Stocks Today (November 14, 2025): AMAT, CDTX, NVDA, AAPL & TSLA

The Nasdaq Composite is under pressure again today as a broad tech selloff and fading hopes for a near‑term Fed rate cut drag Wall Street lower. By late morning U.S. time, the Nasdaq was down around 1.5% in its fifth straight losing session, with chip and EV names once again at the center of the storm. Reuters+1
14 November 2025
······
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

Cidara’s stock has been among the best performers in biotech. According to YTDReturn.com, a US$10,000 investment on 31 Dec 2024 would have grown to ~US$37,943 by 3 Oct 2025 because the share price increased from US$26.88 to US$101.99, a 279.43 % YTD return ytdreturn.com. Zacks similarly reported a 217.8 % YTD rally by late September nasdaq.com, reflecting further gains in October. The stock traded between US$10.14 and US$106.63 over the past year stockanalysis.com and surged 695.5 % year‑on‑year nasdaq.com.
4 October 2025
··
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock Soars After $339M BARDA Flu-Drug Deal – Is CD388 the Next Big Flu-Fighter?

On Friday morning Oct 3, CDTX was trading around $104 per share, up roughly 5.7% from Thursday’s close finviz.com. Trading volumes are high as investors digest the Oct 2 BARDA award news. Cidara’s one-year chart is steeply upward – from around $10 a year ago to over $100 now. Most of that gain occurred since June, after positive Phase 2b results for CD388 and the $402M financing.
3 October 2025
··
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara’s stock has been on a tear in 2025, delivering triple-digit percentage gains. Year-to-date, CDTX has risen about +173% as of late September investing.com, driven by upbeat trial results and investor enthusiasm for its flu program. The stock recently surged over 20% in one day after the Phase 3 acceleration news, reaching an intraday high of approximately $87.75 on Sept. 24 marketbeat.com marketbeat.com. This is effectively a new 52-week high, far above its 52-week low of ~$10 marketbeat.com. By comparison, Cidara’s market capitalization now stands around $2.0–2.3 billion at these prices marketbeat.com, a remarkable appreciation reflecting heightened expectations for the company.
24 September 2025
·
Go toTop